Combo quest

Why NantKwest led Viracta’s B round

By leading Viracta Therapeutics Inc.’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal.

Wicklow Capital,

Read the full 353 word article

How to gain access

Continue reading with a
two-week free trial.